JPRN-jRCT2080220351未知3 期
A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE) in Combination With ZD6474 (ZACTIMA) Versus Docetaxel (TAXOTERE) With Placebo in Subjects With Locally Advanced or Metastatic NSCLC
适应症
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Ages Eligible for Study: 18 Years and above
- •Genders Eligible for Study: Both
- •Inclusion Criteria:
- •- Confirmed locally advanced or metastatic NSCLC
- •- Failure of prior 1st line anti-cancer therapy
排除标准
- •- Cancer other than NSCLC
- •- Prior treatment with docetaxel
- •- Prior 2nd line anti-cancer therapy
研究者
相似试验
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blinded, Multi-Centre Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination with ZD6474 (ZACTIMA™) versus Docetaxel (TAXOTERE™) in combination with Placebo in Patients With Locally Advanced or Metastatic (Stage IIIb – IV) Non-small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-Cancer Therapyon-small cell lung cancerEUCTR2005-004749-32-BEAstraZeneca AB1,240
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blinded, Multi-Centre Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination with ZD6474 (ZACTIMA™) versus Docetaxel (TAXOTERE™) in combination with Placebo in Patients With Locally Advanced or Metastatic (Stage IIIb – IV) Non-small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-Cancer Therapyon-small cell lung cancerEUCTR2005-004749-32-DEAstraZeneca AB1,380
进行中（未招募）
1 期
A Phase III, Randomized, Double-Blinded, Multi-Centre Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination with ZD6474 (ZACTIMA™) versus Docetaxel (TAXOTERE™) in combination with Placebo in Patients With Locally Advanced or Metastatic (Stage IIIb – IV) Non-small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-Cancer Therapyon-small cell lung cancerEUCTR2005-004749-32-GRAstraZeneca AB1,380
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blinded, Multi-Center Study to Assess the Efficacy of Docetaxel TAXOTERE in Combination with ZD6474 ZACTIMA versus Docetaxel TAXOTERE in combination with Placebo in Patients With Locally Advanced or Metastatic Stage IIIb IV Non-small Cell Lung Cancer NSCLC after Failure of 1st Line Anti-Cancer Therapy - NDEUCTR2005-004749-32-ITASTRAZENECA1,240
进行中（未招募）
不适用
A Phase III, Randomized, Double-Blinded, Multi-Centre Study to Assess the Efficacy of Docetaxel (TAXOTERE™) in Combination with ZD6474 (ZACTIMA™) versus Docetaxel (TAXOTERE™) in combination with Placebo in Patients With Locally Advanced or Metastatic (Stage IIIb – IV) Non-small Cell Lung Cancer (NSCLC) after Failure of 1st Line Anti-Cancer TherapyEUCTR2005-004749-32-ATAstraZeneca AB1,240